Business Context and Reporting Period
Company: Park Ha Biological Technology Co., Ltd. (Park Ha Cayman)
Reporting Period: Fiscal year ended October 31, 2025
Business Overview: A Cayman Islands holding company operating in China through subsidiaries and Variable Interest Entities (VIEs). The company develops, sells, and franchises skincare products under the "Park Ha" brand. Operations include direct sales, franchise fees, and "light beauty experience" services.
Listing Status: Listed on Nasdaq Capital Market under symbol "BYAH" (changed from "PHH" in October 2025). The company is an Emerging Growth Company and a Foreign Private Issuer.
Key Financial Metrics
| Metric | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue (Net) | $2,524,843 | $2,381,851 | $2,459,102 |
| Gross Profit | $2,382,317 | $2,186,515 | $2,148,113 |
| Gross Margin | 94.4% | 91.8% | 87.3% |
| Operating Loss | $(24,148,901) | $793,714 | $1,180,554 |
| Net Loss | $(24,364,753) | $478,561 | $852,042 |
| Cash and Equivalents (End of Period) | $3,787,678 | $547,498 | $1,033,634 |
| Operating Cash Flow | $85,852 | $960,470 | $126,537 |
Revenue Composition (FY 2025): Franchise fees accounted for 60% ($1.51M) of revenue, while product sales accounted for 40% ($1.01M). Product sales to franchisees grew 36% year-over-year, while franchise fee revenue declined 10% due to a reduction in the number of franchisees (from 45 to 22).
Material Changes vs. Prior Period
- Significant Net Loss: The company swung from a net income of $478,561 in FY 2024 to a net loss of $24.36 million in FY 2025. This was primarily driven by a $24.07 million share-based compensation expense related to equity incentive plans approved in March and July 2025.
- General & Administrative Expenses: G&A expenses surged from $814,857 in FY 2024 to $25.48 million in FY 2025, largely due to the aforementioned share-based payments and increased professional fees for investor relations and listing services.
- Franchisee Count: The number of franchisees dropped significantly from 45 at the end of FY 2024 to 22 at the end of FY 2025, resulting in lower franchise fee revenue despite higher product sales to remaining franchisees.
- Cash Position: Cash and cash equivalents increased substantially to $3.79 million, driven by $3.74 million in net cash provided by financing activities (proceeds from share issuance).
- Allowance for Credit Losses: The allowance for loans receivable from franchisees increased from $55,520 to $232,876 due to financial difficulties faced by certain franchisees.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary & Outlook:
- Management plans to expand directly operated stores and continue R&D into small molecule peptide hydration technology.
- The company intends to use proceeds from a January 2026 follow-on offering ($2.45 million gross) to expand directly operated stores in China.
- Franchise subsidies were suspended in the second half of 2025.
Unusual Items:
- Share-Based Compensation: A one-time non-cash charge of $24.07 million significantly impacted FY 2025 profitability.
- Reverse Stock Split: A 1-for-50 reverse stock split was approved and became effective in February 2026 to regain compliance with Nasdaq minimum bid price requirements.
Key Risks:
- Internal Controls: Management concluded that internal controls over financial reporting were not effective as of October 31, 2025, citing insufficient in-house personnel with knowledge of U.S. GAAP and SEC rules.
- Regulatory (PRC): Risks related to cybersecurity reviews, data privacy laws (PIPL), and the Holding Foreign Companies Accountable Act (HFCAA) regarding PCAOB inspections of auditors in China.
- VIE Structure: The company relies on contractual arrangements to control VIEs; enforcement of these contracts in Chinese courts is uncertain.
- Franchisee Concentration: High concentration of accounts receivable and loans receivable from franchisees, with increasing bad debt provisions.
Investor Verification Checklist
- Internal Control Weaknesses: Verify the remediation plan for the material weakness in internal controls over financial reporting.
- Franchisee Solvency: Assess the collectability of the $1.02 million in loans receivable from franchisees, given the increased allowance for credit losses.
- Share-Based Compensation: Confirm the vesting schedules and future expense implications of the 2025 equity incentive plans.
- Nasdaq Compliance: Monitor the effectiveness of the reverse stock split in maintaining the minimum $1.00 bid price requirement.
- Regulatory Filings: Verify compliance with CSRC filing requirements for overseas listings and ongoing PCAOB inspection status of the auditor (WWC, P.C.).